Journal
ANNALS OF NEUROLOGY
Volume 84, Issue 6, Pages 940-945Publisher
WILEY
DOI: 10.1002/ana.25374
Keywords
-
Categories
Funding
- National Research Foundation of Korea - Ministry of Science, ICT, and Future Planning, Republic of Korea (Brain Research Program) [2016R1C1B2011815, 2016M3C7A1914002]
- Lee Sueng Moon Research Fund of Seoul National University Hospital [3020170130]
Ask authors/readers for more resources
We investigated the therapeutic potential of the interleukin-6 receptor inhibitor tocilizumab in 7 patients with new onset refractory status epilepticus (NORSE) who remained refractory to conventional immunotherapy with rituximab (n = 5) or without rituximab (n = 2). Status epilepticus (SE) was terminated after 1 or 2 doses of tocilizumab in 6 patients with a median interval of 3 days from the initiation. They had no recurrence of SE during the observation. However, 2 patients experienced severe adverse events related to infection during the tocilizumab therapy. Further prospective controlled studies are warranted to validate the efficacy and safety of tocilizumab in patients with NORSE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available